Is the RSV (respiratory syncytial virus) immunization indicated for this patient?

RSV Immunization Indications by Age

RSV immunization is recommended for all adults ≥75 years and for adults 60-74 years with specific risk factors for severe disease. 1

Age-Based Recommendations

Adults ≥75 Years

• Universal recommendation: All adults in this age group should receive a single dose of RSV vaccine 1
• No additional risk stratification needed
• Single intramuscular injection provides protection for at least two RSV seasons 2

Adults 60-74 Years

RSV vaccination is indicated if one or more of the following risk factors are present 1:

Cardiovascular:

• Chronic heart failure, coronary artery disease, or congenital heart disease (isolated hypertension excluded)

Pulmonary:

• COPD, emphysema, asthma, interstitial lung disease, cystic fibrosis, or chronic respiratory failure

Metabolic/Endocrine:

• Diabetes with complications (chronic kidney disease, neuropathy, retinopathy, end-organ damage, or requiring insulin/SGLT2 inhibitors)
• Severe obesity (BMI ≥40 kg/m²)

Renal:

• End-stage renal disease or hemodialysis dependence

Neurologic:

• Conditions causing impaired airway clearance or respiratory muscle weakness (post-stroke dysphagia, ALS, muscular dystrophy)

Hematologic:

• Chronic conditions like sickle cell disease or thalassemia
• Chronic liver disease (cirrhosis)

Immunocompromise:

• Moderate to severe immunosuppression (including cancer patients, though efficacy data in this population remain limited) 3

Institutional:

• Nursing home residence

Clinical Judgment:

• Frailty, undiagnosed chronic conditions, or residence in remote areas where medical transport is challenging 1

Adults 50-59 Years

• One RSV vaccine (RSVPreF3) is approved for adults 50-59 years at increased risk for RSV disease 2
• Apply similar risk factor assessment as for 60-74 age group
• Consider in patients with severe chronic respiratory or cardiovascular disease 2

Infants and Maternal Immunization

Infants <8 Months

All infants should receive protection through one of three options 4:

1. Maternal RSV vaccination during pregnancy (32-36 weeks gestation, September-January)
2. Nirsevimab monoclonal antibody (weight-based dosing)
3. Clesrovimab monoclonal antibody (single 105 mg dose regardless of weight)

Timing: Administer during October-March in most continental US regions, ideally within 1 week of birth for infants born during RSV season 4

Exception: Infant immunization not needed if mother received RSV vaccine ≥14 days before delivery 4

Vaccine Efficacy Data

The adjuvanted RSVPreF3 vaccine demonstrates superior efficacy 2:

• Season 1: 82.6% efficacy against RSV-associated lower respiratory tract disease
• Severe disease prevention: 94.1% efficacy
• High-risk patients with comorbidities: 94.6% efficacy

Important Clinical Considerations

Dosing: Single dose only; patients who already received RSV vaccine should not receive another dose 1

Coadministration: RSV vaccine can be given with other adult vaccines during the same visit 1

Patient attestation: Self-reported risk factors are sufficient—do not deny vaccination due to lack of medical documentation 1

Cancer patients: While RSV vaccine is FDA-approved for adults ≥60 years, efficacy data in immunocompromised cancer patients remain unknown; clinical judgment should guide decisions 3

Contraindication: History of severe allergic reaction to vaccine components; potential increased risk of Guillain-Barré syndrome should be discussed 1